Ebeling Andrea, Prada Francesco
Photonamic GmbH & Co KG, Eggerstedter Weg 12, 25421 Pinneberg, Germany.
Department of Neurosurgery, Istituto Neurologica Carlo Besta, 20133 Milan, Italy.
Life (Basel). 2025 Apr 29;15(5):718. doi: 10.3390/life15050718.
In recent years, sonodynamic therapy (SDT) has attracted attention as a promising new approach for the treatment of high-grade gliomas, as it is a non-invasive form of therapy that specifically kills tumor cells with limited side effects. SDT combines low-intensity ultrasound with a sonosensitizer to produce cytotoxic effects in tumor cells. 5-Aminolevulinic acid (5-ALA), an endogenous amino acid that is metabolized to protoporphyrin IX (PpIX), has shown promise as a sonosensitizer for malignant gliomas in SDT. Ultrasound can penetrate deeper body regions and activate PpIX, leading to an increase in tumor immunogenicity and induction of apoptosis. This review highlights the current state of knowledge on the mechanisms of action, the results of preclinical, clinical and ongoing studies on 5-ALA-SDT in malignant gliomas, and discusses the future benefits of SDT.
近年来，声动力疗法（SDT）作为一种治疗高级别胶质瘤的有前景的新方法受到关注，因为它是一种非侵入性治疗形式，能特异性杀死肿瘤细胞且副作用有限。SDT将低强度超声与声敏剂结合，在肿瘤细胞中产生细胞毒性作用。5-氨基乙酰丙酸（5-ALA）是一种内源性氨基酸，可代谢为原卟啉IX（PpIX），已显示出作为SDT中恶性胶质瘤声敏剂的潜力。超声可穿透更深的身体区域并激活PpIX，导致肿瘤免疫原性增加并诱导细胞凋亡。本文综述重点介绍了关于5-ALA-SDT在恶性胶质瘤中的作用机制、临床前、临床及正在进行的研究结果的当前知识状态，并讨论了SDT未来的益处。
